MAP3K11

Across TCGA pan-cancer cohorts, MAP3K11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP3K11 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP3K11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K11 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, SARC, and UCEC are the cancer types where MAP3K11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.100	0.698	<.001	72	view →
SARC	DFS	Median	All	0.137	0.613	.004	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	III,IV	0.235	0.677	.030	3	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP3K11–HNSC (DFS)

Open the HNSC breakdown →